Screener
Nuvectis Pharma, Inc. NVCT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| TOTAL ASSETS | $25,398 | $31,709 |
| Liabilities and Shareholders’ Equity | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $4,695 | $6,274 |
| Accrued liabilities | 36 | 115 |
| Employee compensation and benefits | 6,447 | 6,907 |
| TOTAL CURRENT LIABILITIES | 11,178 | 13,296 |
| TOTAL LIABILITIES | 11,178 | 13,296 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s accounts payable?
- Nuvectis Pharma, Inc. (NVCT) reported accounts payable of $4.7M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s accounts payable changed year-over-year?
- Nuvectis Pharma, Inc.'s accounts payable increased by 56.9% year-over-year, from $2.99M to $4.7M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s accounts payable has grown at a 56.1% compound annual growth rate (CAGR), from $1.06M to $6.27M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Nuvectis Pharma, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude